There is a species of Ebola that has killed people in central Africa twice before — in Uganda in 2007 and in the DRC in 2012 — and in the nearly two decades since its discovery, the world produced zero licensed vaccines against it. That fact sits at the center of what is now the worst Bundibugyo virus outbreak on record, with the WHO reporting 906 suspected cases and 223 deaths as of late May 2026, a figure the International Rescue Committee openly states is almost certainly an undercount.

The WHO declared the outbreak a Public Health Emergency of International Concern on May 17, 2026 — a designation that carries real force, triggering coordinated international response mechanisms and formally obligating member states to act. The outbreak originated in the Democratic Republic of the Congo and has crossed into Uganda, where healthcare workers in Kampala have tested positive, confirming the virus's capacity to follow human movement into dense urban corridors. The CDC places the historical case fatality rate for Bundibugyo at 25 to 50 percent, depending on the outbreak — lower than the most feared Ebola Zaire strain, but still a disease that kills between one in four and one in two of those it infects when left without treatment.

On June 1, the Coalition for Epidemic Preparedness Innovations announced it would deploy up to $62 million to fast-track three separate vaccine candidates simultaneously. The logic is probabilistic: no single technology is guaranteed, so run three in parallel. CEPI is committing up to $50 million to Moderna's mRNA-based candidate — by far the largest slice — alongside up to $8.6 million for a shot developed by the University of Oxford and manufactured by the Serum Institute of India, and an initial $3.2 million to the International AIDS Vaccine Initiative. CEPI CEO Dr. Richard Hatchett put it plainly: "With Bundibugyo virus spreading rapidly and no licensed vaccines, every day counts."

The three approaches are deliberately distinct. IAVI's candidate uses a recombinant vesicular stomatitis virus platform — the same backbone technology underlying Merck's Ervebo, the approved vaccine for Ebola Zaire — which has the strongest precedent of any approach in the field. Oxford's candidate uses a different validated technology, while Moderna is deploying its mRNA platform, the same mechanism behind its COVID-19 vaccine. WHO convened experts rated the IAVI rVSV candidate the most promising of the three based on existing safety and immunogenicity data, though all three are experimental and none is ready for deployment in the field today. The Moderna candidate is at the preclinical stage; CEPI's funding would carry it through early clinical testing and manufacturing scale-up if initial results are positive.

None of this will arrive in time to stop the current outbreak from claiming more lives. That is the brutal arithmetic of vaccine development, and no amount of urgency money changes it — though the funding does matter for building the stockpile and the regulatory dossier that would make a faster response possible in a future outbreak. What is more immediately actionable — and more uncomfortable to examine — is how the outbreak got this bad before the world noticed.

The IRC has directly attributed the delayed detection of the outbreak to the collapse of disease surveillance infrastructure in eastern DRC following severe cuts to global health funding. The organization documented suspected cases surging from 246 to 500 in a 96-hour window — a jump consistent with a system that had been failing to count cases, not a sudden biological acceleration. WHO's Contingency Fund for Emergencies, the rapid-response financing instrument designed for exactly this kind of crisis, entered 2026 with just $5.4 million in total donor contributions and was described as close to exhaustion. The frontline capacity that catches viruses early — contact tracers, community health workers, functioning laboratories — had been thinned by budget withdrawals before the first case was confirmed.

The IAVI noted that the current outbreak is "threatening to be the worst ever" — a statement that should be understood in context: there have only been two prior Bundibugyo outbreaks, both comparatively small and geographically contained. This one is neither. It is spreading across a border, has reached a capital city's healthcare workforce, and is doing so without a single approved countermeasure available. Supportive care — fluids, electrolytes, treatment of secondary infections — remains the only intervention with proven benefit.

What this outbreak makes visible is a structural failure that predates any single policy decision: a two-decade window in which Bundibugyo's known existence generated insufficient vaccine investment to produce even one licensed shot. Ervebo took nearly 25 years from the identification of Ebola Zaire to market approval; the public health world then moved on, assuming the harder-to-fund, rarer strains could wait. They could not. The DRC and Uganda are now carrying that cost, and three research teams are racing to build, test, and manufacture something that should have been in a stockpile years ago.